- Home
- PUBM vs FDMT Comparison
PUBM vs FDMT Comparison
Compare PUBM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PUBM | FDMT |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 391.8M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PUBM | FDMT |
|---|---|---|
| Price | $9.21 | $10.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $18.45 | ★ $30.33 |
| AVG Volume (30 Days) | ★ 1.1M | 861.4K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $288,382,000.00 | $120,000.00 |
| Revenue This Year | N/A | $21,181.08 |
| Revenue Next Year | $0.49 | $162.43 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $7.01 | $2.24 |
| 52 Week High | $17.32 | $12.34 |
Technical Indicators
Market Signals| Indicator | PUBM | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | 50.89 |
| Support Level | $8.91 | $9.92 |
| Resistance Level | $9.24 | $11.89 |
| Average True Range (ATR) | 0.35 | 0.80 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 61.62 | 40.61 |
Price Performance
Historical ComparisonAbout PUBM PubMatic Inc.
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.